<DOC>
	<DOCNO>NCT02381847</DOCNO>
	<brief_summary>Patients histological proven advanced gastric cancer ( include cancer esophagogastric junction ( AEG ) without evidence distant metastasis , fulfill inclusion exclusion criterion , recruit study . There two treatment group ( A B ) . The D2 radical gastrectomy apply group . Patients randomize group B treat intraperitoneal ( abdominal cavity ) chemoperfusion cisplatin ( 75mg/m2 max 150mg/m2 max 5L ) . Patients randomize group A accept intraperitoneal chemoperfusion . Patients group receive 6 cycle postoperative chemotherapy ( SOX XELOX ) within 4-12 week surgical procedure follow 24 month .</brief_summary>
	<brief_title>Radical Gastrectomy With/Without HIPEC Advanced Gastric Cancer Patients</brief_title>
	<detailed_description>The objective trial compare treatment patient advance gastric cancer without evidence distant metastasis treat D2 radical gastrectomy intraperitoneal chemoperfusion ( HIPEC ) postoperative chemotherapy ( Group B ) patient treat D2 radical gastrectomy alone postoperative chemotherapy ( Group A ) . The hypothesis trial D2 radical gastrectomy intraperitoneal chemoperfusion ( Group B ) superior D2 radical gastrectomy ( Group A ) term overall survival . The trial design prospective , randomize , open , multicenter parallel group study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histological prove diagnosis peritoneal metastasize gastric cancer include carcinoma AEG . No evidence distant metastasis preoperative examination ( CT/MRI ) demonstrate resectable gastricc cancer T3T4 stage Written inform consent obtain prior commencement trial treatment Any previous chemotherapy radiotherapy , investigational treatment gastric cancer Active systemic infection Patients know interstitial lung disease New York Heart Association classification &gt; 2 Serious cardiac dysrhythmia condition , New York Heart Association classification III IV , congestive cardiac failure cardiac arrhythmia Inadequate renal function begin trial , define GFR less &lt; 60 ml/min Inadequate liver function begin trial , define Bilirubin &gt; 1.5 time ULN Inadequate bone marrow function begin trial , define platelet count less &lt; 150 GPT/L neutrophil granulocyte count less &lt; 1.5 GPT/ Active vaccination within 6 week prior randomisation Active hepatitis B C infection Female patient pregnant breast feed Missing capacity contract contraindication drug use trial Participation another therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>intraperitoneal chemoperfusion</keyword>
</DOC>